 Welcome, everyone. Delighted to have you here at our ninth genomic medicine meeting. On behalf of Carol Bolt to my left, Howard Jacob over there, and the other members of the Genomic Medicine Working Group, I'm thrilled to have everyone here. I think several of you are new to our genomic medicine meetings. This is great. This is one of the purposes of these meetings is to bring groups together who haven't necessarily been talking previously, particularly for this meeting where we wanted to bring together basic science and clinicians to try to figure out how we can speed the translation and also take things back from the bedside that might be observed or problems identified and take them back to the lab for further investigation. So that's kind of the goal of today. I was going to start off by just showing you how these meetings have evolved since 2011. So we began in June of 2011 with a meeting in Chicago where we had sort of an overview of all the groups in the U.S. that we were aware of that were doing genomic medicine. And from that, we realized that there was an awful lot going on, but a lot of it in isolation and really not sort of linked together. And so one of the things we wanted to do with these meetings and other efforts were to bring them together. Immediately from that meeting, we brought forward a program we called ClinAction, which was a workshop about six months later, to try to figure out what variants would be important for groups to report. It turned out that each of these groups were kind of reviewing all the variants that were available at the time and figuring out in isolation what to report. And we thought, well, that's silly. Why not try to do that more as a group endeavor without a lot of duplication? That led to the ClinGen program. We have Aaron Ramos and several other people involved in that program here today. We also added a pharmacogenetic component to our Emerge program that had been ongoing, and that was directly coming out of this meeting, recognizing things that were sort of available and ready to be implemented. Our second meeting about six months after that led to a series of RFAs that then resulted in the Ignite program implementing genomics and clinical practice. That is now six sites that are doing exactly that, trying to study ways of disseminating and implementing genomics and clinical care. Our third meeting focused on payers. We had a subsequent meeting with payers. As you know, getting payers and regulators to address issues in terms of reimbursement and evidence and utility for genomic medicine is a tough nut to crack, and we're continuing to work on that. Our fourth meeting in January of 2014 brought together professional societies looking at physician education and more broadly, clinician education in genomic medicine. That led to our Inter Society Coordinating Committee, now led by Bob Wilden, who is here trying to share educational materials, again, keeping people from doing things in isolation but sharing across groups. Our fifth meeting was with a number of federal agencies, again, trying to develop a federal strategy. This led to collaborations with the Centers for Medicare and Medicaid Services and the FDA. Those lines are dotted not to suggest that genomic medicine caused CMS and the FDA, but at least we did have some interactions with them, and those have borne fruit for us as we've been developing the Precision Medicine Initiative. That's also led to the development of a trans-NIH working group that meets on a monthly basis to review what's going on NIH-wide in genomic medicine. Our sixth meeting in January of 2014, so, sorry, the education meeting was January 2013, but this one in 2014 was of basically global leaders in genomic medicine, those international groups that we were aware of that were doing genomics and clinical care. This has led to an action collaborative in association with the National Academy of Medicine that then subsequently produced a workshop and some efforts in Stevens-Johnson Toxic Epidermal Necrolysis Syndrome, trying to use genomic predictors to prevent that dreaded complication of certain medications. Our seventh meeting in October of 2014 was on genomic clinical decision support, and that has led to a close collaboration with the Digitized Program of the Genomics Roundtable at Mark Williams is heavily involved in. Our eighth meeting in June of last year was to sort of give an overview of all of our programs, kind of take stock and figure out what we needed to do in the future, and one of the things that was clear is that we needed to combine these programs for evidence and really see if we could improve their interactions, as well as maybe adding on some simple measures of clinical utility and personal utility into those programs, and those are sort of continuing to percolate. And also one of the biggest recommendations of that meeting was that we have this group get together, which is to bring together basic scientists and clinical genomicists to further this field. So with that, I will hand it over to Carol.